Seven Fleet Capital Management LP Buys New Holdings in Dianthus Therapeutics, Inc. $DNTH

Seven Fleet Capital Management LP bought a new stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 64,723 shares of the company’s stock, valued at approximately $6,309,198. Dianthus Therapeutics makes up approximately 0.0% of Seven Fleet Capital Management LP’s investment portfolio, making the stock its 22nd largest holding. Seven Fleet Capital Management LP owned 0.12% of Dianthus Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Raymond James Financial Inc. purchased a new position in shares of Dianthus Therapeutics in the second quarter worth approximately $27,000. First Horizon Corp acquired a new stake in shares of Dianthus Therapeutics during the 1st quarter worth about $32,000. Caitong International Asset Management Co. Ltd acquired a new stake in Dianthus Therapeutics in the fourth quarter valued at $40,000. EFG International AG acquired a new position in Dianthus Therapeutics during the second quarter worth approximately $49,000. Finally, Russell Investments Group Ltd. bought a new position in shares of Dianthus Therapeutics during the third quarter worth about $64,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ DNTH traded down $5.70 during trading hours on Friday, reaching $105.84. 376,227 shares of the stock were exchanged, compared to its average volume of 942,277. Dianthus Therapeutics, Inc. has a 52 week low of $22.81 and a 52 week high of $117.88. The firm has a market capitalization of $5.79 billion, a price-to-earnings ratio of -25.50 and a beta of 1.22. The stock’s fifty day simple moving average is $103.13 and its 200 day simple moving average is $86.95.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The business had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. Research analysts predict that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current fiscal year.

Insider Transactions at Dianthus Therapeutics

In related news, EVP Ryan Savitz sold 31,249 shares of the firm’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total value of $3,157,086.47. Following the transaction, the executive vice president directly owned 31,249 shares in the company, valued at approximately $3,157,086.47. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Simon Read sold 2,778 shares of Dianthus Therapeutics stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $117.55, for a total transaction of $326,553.90. Following the completion of the transaction, the director directly owned 2,778 shares in the company, valued at approximately $326,553.90. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 287,084 shares of company stock valued at $29,615,923 over the last quarter. 3.02% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have recently commented on DNTH shares. HC Wainwright raised their price objective on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Wolfe Research reiterated an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Dianthus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $124.27.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.